11 Biotechnology Stocks to Sell Now

Advertisement

For the current week, the overall ratings of 11 biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Sarepta Therapeutics, Inc. (SRPT) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. The stock also earns F’s in Portfolio Grader’s specific subcategories of Earnings Momentum, Equity, Cash Flow and Sales Growth. As of Jan. 21, 2015, 31.4% of outstanding Sarepta Therapeutics, Inc. shares were held short. To get an in-depth look at SRPT, get Portfolio Grader’s complete analysis of SRPT stock.

Stemline Therapeutics, Inc. (STML) is having a tough week. The company’s rating falls from a C to a D. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of STML stock.

Trius Therapeutics, Inc. (TSRX) earns a D this week, falling from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

Slipping from a C to a D rating, Vical Incorporated (VICL) takes a hit this week. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

The rating of MacroGenics, Inc. (MGNX) declines this week from a C to a D. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Margin Growth and Sales Growth also get F’s. To get an in-depth look at MGNX, get Portfolio Grader’s complete analysis of MGNX stock.

CTI BioPharma Corp. (CTIC) earns a D this week, moving down from last week’s grade of C. Cell Therapeutics develops, acquires, and sells new treatments for cancer. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CTIC stock.

The rating of GlycoMimetics, Inc. (GLYC) slips from a C to a D. The stock gets F’s in Earnings Revisions, Equity and Sales Growth. To get an in-depth look at GLYC, get Portfolio Grader’s complete analysis of GLYC stock.

Tenax Therapeutics, Inc. (TENX) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). The stock gets F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The stock currently has a trailing PE Ratio of 116.30. For more information, get Portfolio Grader’s complete analysis of TENX stock.

This is a rough week for Sinovac Biotech (SVA). The company’s rating falls to F from the previous week’s D. Sinovac Biotech researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. The stock gets F’s in Earnings Growth, Earnings Revisions and Sales Growth. The trailing PE Ratio for the stock is 80.80. To get an in-depth look at SVA, get Portfolio Grader’s complete analysis of SVA stock.

This week, Galena Biopharma, Inc. (GALE) drops from a D to an F rating. Galena Biopharma is a biopharmaceuticals company that develops late-stage oncology drugs. The stock gets F’s in Equity and Cash Flow. As of Jan. 21, 2015, 14.6% of outstanding Galena Biopharma, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of GALE stock.

BIND Therapeutics, Inc. (BIND) gets weaker ratings this week as last week’s C drops to a D. The stock gets F’s in Equity, Cash Flow and Sales Growth. To get an in-depth look at BIND, get Portfolio Grader’s complete analysis of BIND stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/11-biotechnology-stocks-to-sell-now-srpt-stml-tsrx/.

©2024 InvestorPlace Media, LLC